GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Net Income

Bottom-line profit, the starting point for calculating cash from operations.

GSK plcNYSE: GSK

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of £437.26M fell 73.4% year over year, behind the +41.0% change in trailing-twelve-month net income. Sequentially, it fell 76.2% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Net income amounted to 17.1% of revenue in FY2025, up 7.7 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of £7.5B (+34.1%) for the fiscal year ending Dec 2026, a slowdown from the +89.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
£437.26M-76.2% QoQ
Last fiscal yearDec 2025
£5.59B+89.5% YoY
LTMJun 2026
£5.62B+41.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-73.4%-24.2%+49.2 pp
1 year+89.5%+34.1%-55.3 pp
3-year CAGR+0.6%+14.2%+13.6 pp
5-year CAGR+9.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

GBP · from the cash flow

Latest · FY2025
5.59B GBP
Year-over-year change
+89.5%
4-year CAGR
+12.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +41.0% is the 2nd highest of 10, against a peer median of -6.4%.
  • Net income amounts to 16.9% of revenue for GSK, versus a peer median of 19.0%.
GSK Competitors
Net Income for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding GSK) —-6.4%+14.3%19.0%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.52B5.49B6.13B2.95B5.59B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
Deferred Income Tax0(965.72M)(1.08B)00
Stock-Based Compensation343M00344M0
Change in Working Capital1.39B(1.67B)(1.06B)2.09B(608.37M)
Accounts Receivables(1.16B)(758.78M)(806.74M)340M0
Inventory51M(331.35M)(527.05M)(294M)0
Accounts Payables0608.5M(18.65M)00
Other Working Capital2.5B(1.19B)288.39M2.04B(608.37M)
Other Non-Cash Items584M3.16B1.61B(1.38B)(153.41M)
Operating Cash Flow7.95B8.16B7.89B6.55B7.14B
Capital Expenditures(2.65B)(1.41B)(1.63B)(2.98B)(1.32B)
Acquisitions (Net)185M(3.79B)(1.72B)1.37B(4.37B)
Purchases of Investments0(177.38M)(152.9M)0(89.98M)
Sales of Investments18M294.4M2.37B21M195.62M
Other Investing Activities(1.03B)(4.43B)14.92M(1.22B)1.46B
Investing Cash Flow(1.78B)(10.88B)(2.4B)(1.23B)(5.72B)
Debt Repayment(2B)(5.69B)(2.95B)(1.17B)1.47B
Common Stock Issued21M30.79M12.43M20M14.67M
Common Stock Repurchased00000
Dividends Paid(4B)(4.27B)(2.79B)(2.44B)(2.51B)
Other Financing Activities(1.61B)11.98B(341.84M)(1.14B)(573.16M)
Financing Cash Flow(7.59B)2.05B(6.07B)(4.73B)(1.59B)
Effect of Forex Changes(29M)(637.97M)(153.84M)(54M)(32.94M)
Net Change in Cash(1.44B)(1.31B)(735.58M)545M(206.06M)
Free Cash Flow5.3B6.75B6.26B3.57B5.82B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.